SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE - News) announced today that it has received the official decision for the grant of another European Patent number 1063921 for its “Optical Biopsy Forceps System and Method of Sampling Tissue.”
The Company developed the Optical Biopsy Probe for use with its proprietary WavSTAT(TM) Optical Biopsy System. It is used by physicians to diagnose whether tissue is normal, pre-cancerous, or cancerous within one second. The WavSTAT(TM) System is currently approved by the FDA for use in detecting cancer in the colon. The probe is unique in that a small optical fiber is located coaxially in its center to diagnose pre-cancers. Then in the same procedure, treatment can begin by removal of the tissue with forceps jaws adjacent to the optical probe. Furthermore, the optical probe can be then used around the margin of the tissue to insure all diseased tissue has been removed.
A new application for detecting pre-cancers in the throat, sometimes called Barrett’s esophagus, is being tested in a clinical trial. Cancer of the esophagus is more than 90% fatal and may develop as a result of chronic heartburn or GERD. Esophageal cancer is growing five times faster than all other cancers.
This news release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from the results discussed in the forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, the Form 10-KSB and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB.and other documents.
For further information contact Jim Hitchin (858) 847-0200 X 201. http://www.spectrascience.com
Source: SpectraScience, Inc.
